Before revision:  We find that for EU countries it will take some time to reach this threshold, given that the new, now dominant, mutations, have a significantly higher infection rate  .
After revision:  We find that for EU countries it will take some time to reach this threshold, given that the new, now dominant, mutations, have a significantly higher infection rate . The urgency of accelerating vaccination is increased by early evidence that the new strains also have a higher mortality risk .